来源：金融界 公开信息显示，现任基金经理齐炜中先生:中国国籍,硕士研究生,金融学硕士。2012年7月加入大成基金 管理有限公司,历任研究部研究员、行业研究主管。2017年2月20日起任大成积极成长混合型证券投资基 金基金经理助理。具备基金从业资格。2020年2月3日起担任大成消费主题混合型证券投资基金基金经 理。2020年02月03日担任大成景阳领先混合型证券投资基金基金经理。2021年03月17日担任大成一带一 路灵活配置混合型证券投资基金基金经理。2021年6月21日担任大成蓝筹稳健证券投资基金基金经理。 2022年11月18日至2025年1月9日任大成消费机遇混合型证券投资基金基金经理。2024年8月5日担任大成 内需增长混合型证券投资基金基金经理。 截止2025年3月31日，大成一带一路灵活配置混合A前十持仓占比合计58.82%，分别为：百亚股份 （9.53%）、孩子王（7.14%）、中芯国际（7.11%）、盐湖股份（6.67%）、匠心家居（5.57%）、永辉 超市（5.08%）、中兴通讯（4.97%）、新诺威（4.96%）、景业智能（3.94%）、成都华微（3.85%）。 6月19日，大成一带一路灵 ...

6月19日，华安医疗创新混合C（013483）下跌2.62%，最新净值1.08元，连续5个交易日下跌，区间累计 跌幅10.35%。 截止2025年3月31日，华安医疗创新混合C前十持仓占比合计40.89%，分别为：泽璟制药-U（5.93%）、 康方生物（5.32%）、科伦博泰生（4.73%）、药明合联（3.91%）、新诺威（3.86%）、康弘药业 （3.81%）、信达生物（3.73%）、百普赛斯（3.69%）、百济神州-U（3.37%）、药明康德（2.54%）。 来源：金融界 据了解，华安医疗创新混合C成立于2021年9月，基金规模0.55亿元，成立来累计收益率-26.17%。从持 有人结构来看，截至2024年末，华安医疗创新混合C的基金机构持有0.07亿份，占总份额的12.96%，个 人投资者持有0.49亿份，占总份额的87.04%。 公开信息显示，现任基金经理刘潇(LIU Xiao)女士:理学硕士。曾任平安资产管理行业研究员。2012年加 入中银基金管理有限公司,曾任研究员。2018年6月至今任中银医疗保健基金基金经理,2019年11月至今任 中银创新医疗基金经理。具备基金从业资格。2020年5月27日至 ...

Group 1 - The core point of the news is that the Huatai Fuhua Medical Service Flexible Allocation Mixed C fund has experienced a decline of 1.56% on June 19, with a cumulative drop of 9.38% over five consecutive trading days, and its latest net value is 1.64 yuan [1] - The fund was established in February 2022, with a total scale of 346 million yuan, and has recorded a cumulative return of -3.47% since inception [1] - As of the end of 2024, institutional investors hold 250 million shares of the fund, accounting for 97.27% of the total shares, while individual investors hold 7 million shares, accounting for 2.73% [1] Group 2 - The current fund manager, Ms. Zhang Wei, has a background in biomedical studies from Cornell University and has held various positions in the pharmaceutical research field before managing multiple funds since 2021 [2] - As of March 31, 2025, the top ten holdings of the Huatai Fuhua Medical Service Flexible Allocation Mixed C fund account for a total of 64.17%, with significant investments in companies such as Heng Rui Pharmaceutical (10.23%) and Ke Long Pharmaceutical (9.09%) [2]

来源：金融界 公开信息显示，现任基金经理赵伟先生:中国,硕士研究生。历任葛兰素史克(上海)医药研发有限公司药 物化学部助理研究员、广发证券股份有限公司投资自营部医药研究员、招商基金管理有限公司研究部医 药组组长及招商基金管理有限公司国际业务部基金经理助理。现任农银汇理基金管理有限公司基金经 理。2019年11月8日至2021年3月5日担任农银汇理中小盘混合型证券投资基金基金经理。2020年1月13日 至2021年3月5日担任农银汇理行业成长混合型证券投资基金基金经理。2020年1月21日至2021年3月5日 任职农银汇理创新医疗混合型证券投资基金基金经理。2017年6月20日至2021年3月5日担任农银汇理医 疗保健主题股票型证券投资基金基金经理。曾任农银汇理中国优势灵活配置混合型证券投资基金基金经 理。2021年03月加入富国基金管理有限公司,2021年7月6日起担任富国精准医疗灵活配置混合型证券投 资基金基金经理。2024年04月23日起担任富国科创板两年定期开放混合型证券投资基金基金经理。 截止2025年3月31日，富国精准医疗混合C前十持仓占比合计69.71%，分别为：百利天恒（9.66%）、海 思科 ...

Core Viewpoint - ICBC Medical Care Stock (000831) has experienced a decline of 1.27% on June 19, with a latest net value of 2.56 yuan, marking a cumulative drop of 7.84% over five consecutive trading days [1] Group 1: Fund Performance - The fund was established in November 2014, with a total scale of 2.724 billion yuan and a cumulative return of 156.40% since inception [1] - As of the end of 2024, institutional investors hold 0.41 million shares, accounting for 3.55% of total shares, while individual investors hold 11.19 million shares, making up 96.45% of total shares [1] Group 2: Fund Management - Current fund manager Zhao Bei has a master's degree and has been with ICBC Credit Suisse since 2010, serving as the fund manager since November 18, 2014 [2] - The current fund manager Ding Yang holds a doctoral degree and joined ICBC Credit Suisse in December 2017, taking over as fund manager on May 5, 2023 [2] Group 3: Portfolio Holdings - As of March 31, 2025, the top ten holdings of ICBC Medical Care Stock account for a total of 39.79%, with major positions including: - Heng Rui Medicine (8.90%) - WuXi AppTec (5.12%) - Aier Eye Hospital (4.94%) - BeiGene (3.77%) - Zai Lab (3.52%) - New Horizon Health (3.27%) - Mindray Medical (2.80%) - Yuwell Medical (2.76%) - United Imaging Healthcare (2.47%) - Innovent Biologics (2.24%) [3]

Group 1 - The core viewpoint of the news is that the ICBC Frontier Medical Stock C (010685) has experienced a decline of 1.24% on June 19, with a cumulative drop of 8.33% over the last five trading days, and its latest net value is 2.94 yuan [1] - The fund was established in November 2020, with a total fund size of 1.38 billion yuan, and has recorded a cumulative return of -10.43% since inception [1] - As of the end of 2024, institutional investors hold 0.20 million shares, accounting for 3.55% of the total shares, while individual investors hold 5.51 million shares, making up 96.45% of the total [1] Group 2 - The current fund manager, Zhao Bei, has a master's degree and has been with ICBC Credit Suisse since 2010, currently serving as the deputy director of the research department and head of the healthcare research team [2] - Zhao has managed several funds, including the ICBC Healthcare Industry Stock Fund since November 2014 and the ICBC Frontier Medical Stock Fund since February 2016 [2] - As of March 31, 2025, the top ten holdings of ICBC Frontier Medical Stock C account for a total of 59.05%, with major holdings including Heng Rui Medicine (10.11%), Kelun Pharmaceutical (8.01%), and WuXi AppTec (7.72%) [2]

来源：金融界 公开信息显示，现任基金经理刘泽序先生:中国,硕士研究生,2016年3月至2022年3月期间任中信证券股份 有限公司研究部行业分析师,2022年3月至2023年6月期间任上海景林资产管理有限公司投资研究部分析 师。2023年6月加入国投瑞银基金管理有限公司基金投资部。2023年9月12日起担任国投瑞银创新医疗灵 活配置混合型证券投资基金基金经理。2024年5月1日担任国投瑞银医疗保健行业灵活配置混合型证券投 资基金基金经理。 截止2025年3月31日，国投瑞银医疗保健混合C前十持仓占比合计39.42%，分别为：恒瑞医药 （6.09%）、泽璟制药-U（5.28%）、科伦药业（5.22%）、药明康德（3.98%）、昆药集团（3.75%）、 泰格医药（3.67%）、东阿阿胶（3.45%）、奥赛康（2.86%）、凯莱英（2.58%）、新诺威（2.54%）。 6月19日，国投瑞银医疗保健混合C（011082）下跌1.23%，最新净值0.87元，连续5个交易日下跌，区间 累计跌幅7.99%。 据了解，国投瑞银医疗保健混合C成立于2020年12月，基金规模0.16亿元，成立来累计收益率-35.71%。 从持有人 ...

Group 1 - The core point of the article highlights the performance and holdings of the Guangfa Healthcare Stock A fund, which has a recent net value of 1.8385 yuan, reflecting a decline of 1.37% [1] - The fund's performance over the past month shows a return of 4.59%, ranking 34 out of 316 in its category; over the past six months, it has returned 11.72%, ranking 41 out of 311; and since the beginning of the year, it has achieved a return of 13.74%, ranking 36 out of 311 [1] - The top ten holdings of the fund account for a total of 48.15%, with significant positions in companies such as Zai Lab (10.52%), Kelun Pharmaceutical (8.39%), and others [1] Group 2 - Guangfa Healthcare Stock A fund was established on August 10, 2017, and as of March 31, 2025, it has a total scale of 5.237 billion yuan, managed by fund manager Wu Xingwu [1] - Wu Xingwu has a background in finance with a master's degree in science and has held various positions in fund management, including roles at Morgan Stanley Huaxin Fund Management and Guangfa Fund Management [2]

Core Insights - The latest net value of Zhongyin Innovation Medical Mixed A Fund (007718) is 1.8893 CNY, with a growth of 0.64% [1] - The fund has shown a one-month return of 16.39%, ranking 76 out of 4640 in its category; a six-month return of 50.83%, ranking 25 out of 4486; and a year-to-date return of 57.01%, ranking 24 out of 4506 [1] Fund Holdings - The top ten stock holdings of Zhongyin Innovation Medical Mixed A Fund account for a total of 70.44%, with the largest positions being: - Kelun-Botai (9.77%) - Heng Rui Pharmaceutical (9.39%) - Innovent Biologics (8.54%) - CanSino Biologics (8.24%) - CanSino-B (6.59%) - New Horizon Health (6.27%) - BeiGene-U (6.02%) - Baillie Gifford (5.89%) - Hutchison China MediTech (5.16%) - Hansoh Pharmaceutical (4.57%) [1] Fund Management - Zhongyin Innovation Medical Mixed A Fund was established on November 13, 2019, and as of March 31, 2025, it has a total asset size of 2.613 billion CNY [1] - The fund manager is Zheng Ning, who has a background in stock research and has held positions at various asset management companies before joining Zhongyin Fund Management in 2022 [2]

Core Insights - The latest net value of ICBC Medical Care Stock (000831) is 2.5970 yuan, reflecting a decrease of 0.65% [1] - The fund has shown a monthly return of 3.76%, ranking 221 out of 922 in its category, a six-month return of 11.08% with a ranking of 162 out of 898, and a year-to-date return of 13.95%, ranking 134 out of 901 [1] Fund Holdings - The top ten holdings of ICBC Medical Care Stock account for a total of 39.79%, with the largest positions being: - Heng Rui Medicine (8.90%) - WuXi AppTec (5.12%) - Aier Eye Hospital (4.94%) - BeiGene (3.77%) - Zai Lab (3.52%) - New Horizon Health (3.27%) - Mindray Medical (2.80%) - Yuyue Medical (2.76%) - United Imaging Healthcare (2.47%) - Innovent Biologics (2.24%) [1] Fund Management - ICBC Medical Care Stock was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan [1] - The fund is managed by Zhao Bei and Ding Yang, with Zhao having extensive experience in healthcare research and fund management since joining ICBC Credit Suisse in 2010 [2]